Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7K360)

Drug Name

AL-408 Drug Info

Synonyms

AL-108 analog (neurodegenerative diseases), Allon

Indication

Disease Entry	ICD 11	Status	REF
Central nervous system disease	8A04-8D87	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Microtubule-associated protein tau (MAPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMT-X	DMOFIBM	Acute myeloid leukaemia	2A60	Phase 3	[2]
Davunetide	DMD7K9X	Cognitive impairment	6D71	Phase 3	[1]
TRx0237	DM0QNF4	Alzheimer disease	8A20	Phase 3	[3]
E2814	DMZ3Q59	Alzheimer disease	8A20	Phase 2/3	[4]
PBT-2	DMKWGS1	Alzheimer disease	8A20	Phase 2	[5]
RG6100	DMEFD0B	Alzheimer disease	8A20	Phase 2	[6]
Tau-binding PET tracer	DM9QFW2	Alzheimer disease	8A20	Phase 2	[1]
BIIB092	DM263RP	Progressive supranuclear palsy	8A00.10	Phase 2	[6]
Semorinemab	DMA17VD	Alzheimer disease	8A20	Phase 2	[7]
Bepranemab	DMRQIJO	Alzheimer disease	8A20	Phase 2	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Microtubule-associated protein tau (MAPT)	TTS87KH	TAU_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
2	Clinical pipeline report, company report or official report of TauRx.
3	Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
4	Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
5	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
8	Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.